Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

6.845 -0.115 (-1.65%)

Delayed Quote Updated: 10:46 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 12, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Why Are Ocular Therapeutix Shares Trading Higher Today? ↗

October 11, 2021

The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 11, 2021

Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is...

Via Benzinga

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

October 11, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

28 Stocks Moving In Monday's Mid-Day Session ↗

October 11, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

September 28, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

September 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

September 13, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 07, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

This Exciting Biopharma Could Earn You 55% in 12 Months ↗

August 22, 2021

When patients see more clearly, so too should investors.

Via The Motley Fool

4 Reasons I Just Bought Ocular Therapeutix Stock ↗

August 21, 2021

This company's drug delivery technology just isn't getting the appreciation it deserves right now.

Via The Motley Fool

Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference

August 10, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update

August 09, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases ↗

August 06, 2021

Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 05, 2021

Gainers Sensus Healthcare (NASDAQ:SRTS) ...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗

August 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases

August 05, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration

July 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results

July 28, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

July 23, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs ↗

July 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 22, 2021

Gainers Xenetic Biosciences (NASDAQ:XBIO...

Via Benzinga

Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million

July 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration

June 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 08, 2021

Gainers Aethlon Medical (NASDAQ:AEMD) sto...

Via Benzinga

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

May 26, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.